{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-251712","form_type":"8-K","ticker":"URGN","cik":"0001668243","company_name":"UroGen Pharma Ltd.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.169977+00:00","generated_at":"2026-05-30T04:38:15.924468+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"UroGen Q3 revenue $25.2M, net loss $23.7M; UGN-102 PDUFA June 2025; cuts FY revenue view","bullets":["JELMYTO Q3 net product revenue $25.2M (+21% YoY from $20.9M).","Net loss $23.7M ($0.55/share) vs $21.9M ($0.68/share) in Q3 2023.","NDA for UGN-102 accepted; PDUFA target action date June 13, 2025.","Full-year 2024 JELMYTO revenue expected below prior guidance low end; still low double-digit YoY growth.","Cash, equivalents, marketable securities $254.2M as of Sept 30, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-251712","json":"https://secwatch.observer/filing/0001193125-24-251712.json","markdown":"https://secwatch.observer/filing/0001193125-24-251712.md","text":"https://secwatch.observer/filing/0001193125-24-251712.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1668243/000119312524251712/0001193125-24-251712-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1668243/000119312524251712/d910412d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:38:15.924468+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}